Metastatic cancer (also referred as advanced or stage 4 cancer) occurs when the primary cancer has spread to other parts of the body via the lymphatic or blood circulation systems. Although it can spread to almost every organ in the body, some cancers, such as breast cancer, can spread to the lungs, liver, bones, and brain.The metastatic cancer drug is supportive and aims to reduce the severity of the symptoms.
This report contains market size and forecasts of Metastatic Cancer Drug in Global, including the following market information:
Global Metastatic Cancer Drug Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Metastatic Cancer Drug market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period 2022-2028.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Trastuzumab Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Metastatic Cancer Drug include AstraZeneca, Merck, Pfizer, Celgene, AKRON, Novartis, Galen, Pacira BioSciences and Johnson & Johnson, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Metastatic Cancer Drug companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Metastatic Cancer Drug Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Metastatic Cancer Drug Market Segment Percentages, by Type, 2021 (%)
Trastuzumab
Pertuzumab
Global Metastatic Cancer Drug Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Metastatic Cancer Drug Market Segment Percentages, by Application, 2021 (%)
Hospitals
Specialty Clinics
Global Metastatic Cancer Drug Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Metastatic Cancer Drug Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Metastatic Cancer Drug revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Metastatic Cancer Drug revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
AstraZeneca
Merck
Pfizer
Celgene
AKRON
Novartis
Galen
Pacira BioSciences
Johnson & Johnson
Fresenius Kabi AG
Spectrum Pharmaceuticals
Takeda Pharmaceutical
Teva Pharmaceutical Industries
Cipla
Sun Pharmaceutical Industries
Shanghai Fosun Pharmaceutical
Ingenus